Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
ByAinvest
Monday, Aug 25, 2025 8:04 am ET1min read
PHAT--
Management representatives from Phathom Pharmaceuticals will conduct one-on-one meetings throughout both conferences. These events are expected to provide investors with a comprehensive overview of the company's pipeline, current market position, and future growth prospects.
The Cantor Global Healthcare Conference 2025 will take place in New York, NY, from September 3 to 5, 2025. The live webcast for the Phathom Pharmaceuticals presentation is scheduled for September 3 at 9:10 am EDT. The H.C. Wainwright 27th Annual Global Investment Conference will be held in New York, NY, from September 8 to 10, 2025, with the live webcast for Phathom Pharmaceuticals' presentation set for September 8 at 1:00 pm EDT. Both webcasts and archived recordings will be available on the Phathom Pharmaceuticals website for up to 90 days following the events [1].
Phathom Pharmaceuticals markets vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment in the United States [2].
References:
[1] https://www.marketscreener.com/news/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ce7c50d8d889f324
[2] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Phathom Pharmaceuticals will participate in the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in September. Management will participate in 1x1 meetings throughout the conferences and there will be live webcasts. The company markets vonoprazan for various gastrointestinal diseases in the US.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 9:10 am EDT and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 1:00 pm EDT.Management representatives from Phathom Pharmaceuticals will conduct one-on-one meetings throughout both conferences. These events are expected to provide investors with a comprehensive overview of the company's pipeline, current market position, and future growth prospects.
The Cantor Global Healthcare Conference 2025 will take place in New York, NY, from September 3 to 5, 2025. The live webcast for the Phathom Pharmaceuticals presentation is scheduled for September 3 at 9:10 am EDT. The H.C. Wainwright 27th Annual Global Investment Conference will be held in New York, NY, from September 8 to 10, 2025, with the live webcast for Phathom Pharmaceuticals' presentation set for September 8 at 1:00 pm EDT. Both webcasts and archived recordings will be available on the Phathom Pharmaceuticals website for up to 90 days following the events [1].
Phathom Pharmaceuticals markets vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment in the United States [2].
References:
[1] https://www.marketscreener.com/news/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ce7c50d8d889f324
[2] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet